Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 1;40(13):1450-1463.
doi: 10.1200/JCO.21.02062. Epub 2022 Feb 16.

Mortality After Late Breast Cancer Recurrence in Denmark

Affiliations

Mortality After Late Breast Cancer Recurrence in Denmark

Rikke Nørgaard Pedersen et al. J Clin Oncol. .

Abstract

Purpose: Late breast cancer (BC) recurrence (ie, ≥ 10 years after primary diagnosis) may have a more favorable prognosis than earlier recurrence. We investigated the risk of BC death after late recurrence, identified prognostic factors, and compared survival after early and late recurrence.

Methods: Using the Danish Breast Cancer Group and other nationwide databases, we identified women with early or late BC recurrence during 2004-2018, who were alive 6 months after recurrence. We followed them until BC death, death from other causes, emigration, 10 years, or December 31, 2018, whichever came first. We calculated mortality rates (MRs) per 1,000 person-years (PY) and cumulative BC mortality, for early versus late recurrence, and by characteristics of the primary tumor and the late recurrence. Using Cox regression, we calculated adjusted hazard ratios (HRs) for BC death, accounting for death from other causes as competing risks.

Results: Among 2,004 patients with late recurrence, 721 died of BC with a median survival time of 10 years (MR = 84.8 per 1,000 PY; 10-year cumulative mortality = 50%). Among 1,528 patients with early recurrence, 1,092 BC deaths occurred with a median survival time of 4 years (MR = 173.9 per 1,000 PY; 10-year cumulative mortality = 72%). We observed a lower hazard of BC-specific death among patients who developed late compared with early recurrence (hazard ratio = 0.72; 95% CI, 0.62 to 0.85). Advanced stage at primary diagnosis, distant metastases, adjuvant treatment for locoregional recurrence, and systemic treatment for distant recurrence were associated with increased mortality after late recurrence. Breast-conserving surgery at primary diagnosis, locoregional recurrence, and surgery for recurrence were associated with lower mortality after late recurrence.

Conclusion: Patients with late recurrence had more favorable prognosis than patients with early recurrence. The localization of recurrent disease was the main prognostic factor for BC death.

PubMed Disclaimer

Conflict of interest statement

Lene MellemkjærEmployment: Novo Nordisk (I)Stock and Other Ownership Interests: Novo Nordisk (I) Bent EjlertsenResearch Funding: Roche (Inst), Novartis (Inst), Pfizer (Inst), AstraZeneca (Inst), MSD (Inst)Travel, Accommodations, Expenses: Roche, AstraZeneca, MSD Mette NørgaardResearch Funding: Amgen (Inst), Merck KGaA (Inst)No other potential conflicts of interest were reported.

Publication types

LinkOut - more resources